-
La Roche-Posay launches new acne treatment
NEW YORK — In an effort to help those suffering from acne, La Roche-Posay has introduced its new Effaclar K Daily Renovating Anti-Relapse Acne Treatment 1, a daily treatment to address the ongoing, recurring life cycle of acne.
For the first time in a La Roche-Posay product, retinyl linoleate (a vitamin A derivative), salicylic acid and La Roche-Posay's exclusive lipo-hydroxy acid (LHA) molecule are combined to help treat mild acne and prevent its reoccurrence in acne sufferers of all ages.
-
Study: Tradjenta reduces blood sugar, weight among patients
SAN DIEGO — New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.
Boehringer Ingelheim and Eli Lilly presented data from the study of Tradjenta (linagliptin) at the American Diabetes Association’s 71st Scientific Sessions in San Diego last weekend. The study showed reductions in blood sugar and weight, and a low incidence of abnormally low blood sugar, known as hypoglycemia.
The FDA approved Tradjenta as a treatment for Type 2 diabetes in May.